Baudax Bio, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BXRXQ research report →
Companywww.baudaxbio.com
Baudax Bio, Inc. , a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.
- CEO
- Geraldine A. Henwood
- IPO
- 2024
- Employees
- 9
- HQ
- Malvern, PA, US
Price Chart
Valuation
- Market Cap
- $4.36K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.06
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -452.32%
- Op Margin
- -4476.99%
- Net Margin
- -4633.18%
- ROE
- 1067.45%
- ROIC
- 974.83%
Growth & Income
- Revenue
- $1.27M · 17.50%
- Net Income
- $-58,795,000 · -197.41%
- EPS
- $-177.30 · 50.91%
- Op Income
- $-56,813,000
- FCF YoY
- 43.78%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -11.87
- Avg Volume
- 3.31K
Get TickerSpark's AI analysis on BXRXQ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BXRXQ Coverage
We haven't published any research on BXRXQ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BXRXQ Report →